| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Joseph M Gozgit, Geraldine Bebernitz, Pankaj Patil, Minwei Ye, Julie Parmentier, Jiaquan Wu, Nancy Su, Tao Wang, Stephanos Ioannidis, Audrey Davies, Dennis Huszar, Michael Zind. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. The Journal of biological chemistry. vol 283. issue 47. 2009-01-22. PMID:18775810. |
we provide evidence that jak2 inhibition induces apoptosis by direct and indirect regulation of the anti-apoptotic protein bcl-xl. |
2009-01-22 |
2023-08-12 |
human |
| Gang Chen, Jiang Wu, Caixia Sun, Meng Qi, Chunhua Hang, Yi Gong, Xiaodong Han, Jixin Sh. Potential role of JAK2 in cerebral vasospasm after experimental subarachnoid hemorrhage. Brain research. vol 1214. 2008-09-19. PMID:18471803. |
in experiment 2, we chose the maximum time point of jak2 activation and assessed the effect of ag490 (a specific jak2 inhibitor) on regulation of cerebral vasospasm and endothelial apoptosis. |
2008-09-19 |
2023-08-12 |
Not clear |
| Daniel B Lipka, Linda S Hoffmann, Florian Heidel, Boyka Markova, Marie-Christine Blum, Frank Breitenbuecher, Stefan Kasper, Thomas Kindler, Ross L Levine, Christoph Huber, Thomas Fische. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular cancer therapeutics. vol 7. issue 5. 2008-08-22. PMID:18483305. |
ls104, a non-atp-competitive small-molecule inhibitor of jak2, is potently inducing apoptosis in jak2v617f-positive cells. |
2008-08-22 |
2023-08-12 |
Not clear |
| Daniel B Lipka, Linda S Hoffmann, Florian Heidel, Boyka Markova, Marie-Christine Blum, Frank Breitenbuecher, Stefan Kasper, Thomas Kindler, Ross L Levine, Christoph Huber, Thomas Fische. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular cancer therapeutics. vol 7. issue 5. 2008-08-22. PMID:18483305. |
in this report, we characterize the small-molecule ls104 as a novel non-atp-competitive jak2 inhibitor: treatment of jak2v617f-positive cells with ls104 resulted in dose-dependent induction of apoptosis and inhibition of jak2 autophosphorylation and of downstream targets. |
2008-08-22 |
2023-08-12 |
Not clear |
| Daniel B Lipka, Linda S Hoffmann, Florian Heidel, Boyka Markova, Marie-Christine Blum, Frank Breitenbuecher, Stefan Kasper, Thomas Kindler, Ross L Levine, Christoph Huber, Thomas Fische. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular cancer therapeutics. vol 7. issue 5. 2008-08-22. PMID:18483305. |
in line with these data, combination treatment using ls104 plus an atp-competitive jak2 inhibitor (jak inhibitor i) led to synergistically increased apoptosis in jak2v617f-positive cells. |
2008-08-22 |
2023-08-12 |
Not clear |
| Srdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, David Harris, Jorge Cortes, Francis J Giles, Hagop Kantarjian, Waldemar Priebe, Zeev Estro. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 14. issue 3. 2008-06-19. PMID:18245540. |
wp1066, a novel jak2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the jak2 v617f mutation. |
2008-06-19 |
2023-08-12 |
human |
| F Shafiei, F Rahnama, L Pawella, M D Mitchell, P D Gluckman, P E Lobi. DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells. Oncogene. vol 27. issue 18. 2008-05-19. PMID:17998942. |
autocrine hgh stimulation of dnmt3a and dnmt3b expression was mediated by jak2 and src kinases, and treatment of mammary carcinoma cells with the dnmt inhibitor, 5'-aza-2'-deoxycytidine (aza), abrogated autocrine hgh-stimulated cellular proliferation, apoptosis and anchorage-independent growth. |
2008-05-19 |
2023-08-12 |
human |
| Hui-Fang Xie, Ru-Xiang Xu, Ji-Peng Wei, Xiao-Dan Jiang, Zhen-Hua Li. [P-JAK2 and P-STAT3 protein expression and cell apoptosis following focal cerebral ischemia-reperfusion injury in rats]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. vol 27. issue 2. 2008-05-15. PMID:17355939. |
to investigate the changes in phosphorylated jak2 and stat3 protein expression of and cell apoptosis following focal cerebral ischemia-reperfusion injury in rats. |
2008-05-15 |
2023-08-12 |
rat |
| Ahmed S Sultan, Hassan Brim, Zaki A Sheri. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer science. vol 99. issue 2. 2008-04-22. PMID:18271926. |
hyperactivation of jak2 and stat5a in t-47d cells induces alveolar-like structures, mamospheres, with marked lumen formation through central apoptosis and restores a polarized epithelial phenotype. |
2008-04-22 |
2023-08-12 |
human |
| Yukiyo Yokomaku, Toshiro Sugimoto, Shinji Kume, Shin-ichi Araki, Keiji Isshiki, Masami Chin-Kanasaki, Masayoshi Sakaguchi, Norihisa Nitta, Masakazu Haneda, Daisuke Koya, Takashi Uzu, Atsunori Kashiwag. Asialoerythropoietin prevents contrast-induced nephropathy. Journal of the American Society of Nephrology : JASN. vol 19. issue 2. 2008-02-29. PMID:18184858. |
contrast-induced apoptosis of renal tubular cells was inhibited by asialoerythropoietin both in vivo and in vitro, and this effect was blocked by a janus kinase 2 (jak2) inhibitor in vitro. |
2008-02-29 |
2023-08-12 |
rat |
| H M Yu, J L Zhi, Y Cui, E H Tang, S N Sun, J Q Feng, P X Che. Role of the JAK-STAT pathway in protection of hydrogen peroxide preconditioning against apoptosis induced by oxidative stress in PC12 cells. Apoptosis : an international journal on programmed cell death. vol 11. issue 6. 2007-11-01. PMID:16547593. |
it was shown that (1) preconditioning with 100 micromol/l h(2)o(2) can markedly protect pc12 cells against apoptosis and cytotoxicity induced by 300 micromol/l h(2)o(2); (2) the expression and tyrosine phosphorylation of jak2, not jak1 were rapidly increased at 5 min after h(2)o(2) preconditioning; (3) the expression of stat1 and stat3 were significantly increased at 15 min after h(2)o(2) preconditioning, and the ptyr-stat1 and ptyr-stat3 were markedly increased at 60 min after h(2)o(2) preconditioning; (4) pretreatment with the jak inhibitor ag-490 (10 micromol/l) 20 min before h(2)o(2) preconditioning blocked not only the activation of jak2, stat1 and stat3, but also the cytoprotection of h(2)o(2) preconditioning against apoptosis and cytotoxicity induced by oxidative stress. |
2007-11-01 |
2023-08-12 |
Not clear |
| C M Logar, P T Brinkkoetter, R D Krofft, J W Pippin, S J Shanklan. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney international. vol 72. issue 4. 2007-09-18. PMID:17554257. |
pretreatment with darbepoetin alfa significantly reduced podocyte apoptosis with this effect involving intact janus family protein kinase-2 (jak2) and akt signaling pathways. |
2007-09-18 |
2023-08-12 |
mouse |
| Nathan J Lanning, Christin Carter-S. Recent advances in growth hormone signaling. Reviews in endocrine & metabolic disorders. vol 7. issue 4. 2007-07-24. PMID:17308965. |
gh binding of ghr activates the tyrosine kinase janus kinase 2 (jak2), thus initiating a multitude of signaling cascades that result in a variety of biological responses including cellular proliferation, differentiation and migration, prevention of apoptosis, cytoskeletal reorganization and regulation of metabolic pathways. |
2007-07-24 |
2023-08-12 |
Not clear |
| R A Mesa, A Tefferi, T S Lasho, D Loegering, R F McClure, H L Powell, N T Dai, D P Steensma, S H Kaufman. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. vol 20. issue 10. 2006-11-07. PMID:16871275. |
indeed, apoptotic resistance was greatest in mmm neutrophils with high mutant allele burden (median 22% apoptosis, n=5) than with intermediate burden (median 39%, n=23) or wild-type jak2 (median 47%, n=22; p=0.008). |
2006-11-07 |
2023-08-12 |
Not clear |
| R A Mesa, A Tefferi, T S Lasho, D Loegering, R F McClure, H L Powell, N T Dai, D P Steensma, S H Kaufman. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. vol 20. issue 10. 2006-11-07. PMID:16871275. |
these results suggest that mutant jak2 contributes to mmm pathogenesis by constitutively phosphorylating stat3 and diminishing myeloid cell apoptosis. |
2006-11-07 |
2023-08-12 |
Not clear |
| Ann Zeuner, Francesca Pedini, Michele Signore, Giusy Ruscio, Carlo Messina, Agostino Tafuri, Gabriella Girelli, Cesare Peschle, Ruggero De Mari. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood. vol 107. issue 9. 2006-05-24. PMID:16384930. |
jak2 mutation was associated in pv erythroblasts with cytokine-independent activation of the jak2 effectors akt/pkb and erk/map and with a deregulated expression of c-flip(short), a potent cellular inhibitor of death receptor-induced apoptosis. |
2006-05-24 |
2023-08-12 |
Not clear |
| H Quentmeier, R A F MacLeod, M Zaborski, H G Drexle. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. vol 20. issue 3. 2006-04-25. PMID:16408098. |
confirming the importance of the mutated jak2 protein for growth and prevention of apoptosis, jak2mu cell lines displayed higher sensitivities to jak2 inhibition than jak2wt cell lines. |
2006-04-25 |
2023-08-12 |
Not clear |
| Jalal Ahmed-Choudhury, Kevin T Williams, Lawrence S Young, David H Adams, Simon C Affor. CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cellular signalling. vol 18. issue 4. 2006-04-18. PMID:15970430. |
cd40 mediated human cholangiocyte apoptosis requires jak2 dependent activation of stat3 in addition to activation of jnk1/2 and erk1/2. |
2006-04-18 |
2023-08-12 |
human |
| Jalal Ahmed-Choudhury, Kevin T Williams, Lawrence S Young, David H Adams, Simon C Affor. CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cellular signalling. vol 18. issue 4. 2006-04-18. PMID:15970430. |
jnk, erk and jak2 inhibitors partially abrogated apoptosis and when used in combination reduced it to basal levels. |
2006-04-18 |
2023-08-12 |
human |
| D Chappell, P A Tilbrook, T Bittorf, S M Colley, G T Meyer, S P Klinke. Prevention of apoptosis in J2E erythroid cells by erythropoietin: involvement of JAK2 but not MAP kinases. Cell death and differentiation. vol 4. issue 2. 2006-03-02. PMID:16465216. |
prevention of apoptosis in j2e erythroid cells by erythropoietin: involvement of jak2 but not map kinases. |
2006-03-02 |
2023-08-12 |
Not clear |